The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitis.

• Durvalumab consolidation was a significant moderator of this effect showing a highly significant interaction effect with the dose response. • There was a considerable inter-individual heterogeneity in lung infiltrate partial volumes. • Pulmonary infiltrate volumes at 35–40 Gy were a strong predictive factor for pneumonitis grade II.

also in 132,142 other papers